Filament Health Corp. announced the appointment of Michael Messinger, CPA, to its Board of Directors . Mr. Messinger will also serve as the Chair of the Company's Audit Committee.

Mr. Messinger has more than 20 years of experience leading finance as well as other support functions for drug discovery and development organizations. He has extensive understanding of clinical development across a variety of therapeutic areas including neurology, metabolic disorders, gastrointestinal disorders, immunology, ophthalmology and infectious diseases. Prior to joining Filament's Board, Mr. Messinger held executive and financial reporting roles with ContraFect Corporation (ContraFect) and Lexicon Pharmaceuticals Inc. (Lexicon).

As Chief Financial Officer of ContraFect, Mr. Messinger raised over $275 million of funding in multiple financings, including ContraFect's initial public offering in 2014. Mr. Messinger served as Director of Research and Development Finance at Lexicon before joining ContraFect. While at Lexicon, Mr. Messinger was responsible for the financial management of Lexicon's partnership with Symphony Capital, LLC, in addition to coordinating fiscal and program management concerning Lexicon's development programs. Prior to working at Lexicon, he served as Controller of Coelacanth Corporation (Coelacanth) for two years, leading the effort for the sale of Coelacanth to Lexicon.

Mr. Messinger received his Bachelor of Business Administration from the University of Michigan. He began his career as an auditor at Ernst & Young LLP.